Answer:
The monoclonal antibodies are a therapy for cancer.
Step-by-step explanation:
In the specific case of monoclonal antibodies (mAbs) these are glycoproteins produced by the clone of a hybrid cell (created from the fusion of a single stem cell of the immune system and a tumor plasma cell) and designed to attack a concrete antigen
Monoclonal antibodies are a relatively new type of "targeted" therapy for cancer. Antibodies are part of the immune system. Normally, the body creates antibodies in response to an antigen (such as a protein in a microbe) that enters the body. The antibodies bind to the antigen to label it so that the body's immune system destroys it. In the laboratory, scientists analyze specific antigens on the surface of cancer cells (target) to determine a protein that corresponds to the antigen. Then, using animal and human proteins, scientists work to create a special antibody that adheres to the target antigen. An antibody will adhere to the antigen that corresponds to it in the same way that a key fits into your lock. This technology allows to direct the treatment towards specific cells, causing a lower toxicity for healthy cells. Monoclonal antibody therapy can only be used in cancers whose antigens (and their respective antibodies) have been identified. The following are monoclonal antibodies:
Alemtuzumab
Gemtuzumab ozogamycin
Rituximab
Trastuzumab
Ibritumomab tiuxetan